Catalyst fixes party name in FIRDAPSE settlement

Catalyst Pharmaceuticals filed an amended current report to correct a naming error in an earlier update about a patent litigation settlement related to its FIRDAPSE® patents.

Rhea-AI Filing Summary

Catalyst Pharmaceuticals filed an amended current report to correct a naming error in an earlier update about a patent litigation settlement related to its FIRDAPSE® patents. The company had reported a prior settlement with “Inventia Life Science Pty Ltd,” but clarified that the correct party is Inventia Healthcare Limited.

The amendment states that no other terms of the previously disclosed settlement with Lupin or the related press release were changed. Catalyst attached the corrected August 26, 2025 press release as an exhibit, confirming that the update is purely to fix the identity of the earlier settling party.

8-K Event Classification

Item 9.01 — Financial Statements and Exhibits

1 item

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Catalyst Pharmaceuticals (CPRX) change in its amended 8-K/A filing?

Catalyst Pharmaceuticals corrected the name of a previously settling party in its FIRDAPSE® patent litigation disclosures. The company clarified that the correct entity is Inventia Healthcare Limited, not Inventia Life Science Pty Ltd, and stated no other settlement or press release terms were changed.

Which company was correctly identified in Catalyst Pharmaceuticals’ FIRDAPSE patent litigation?

The correctly identified party is Inventia Healthcare Limited. Catalyst Pharmaceuticals explained that earlier disclosures and a press release mistakenly named Inventia Life Science Pty Ltd, and the amended report and updated press release now reflect the accurate counterparty name.

Does Catalyst Pharmaceuticals’ 8-K/A change the terms of its settlement with Lupin?

The 8-K/A does not change the settlement terms with Lupin. Catalyst specifically notes that the only modification is correcting the identity of a previously settling party in FIRDAPSE® patent litigation, with all other aspects of the original press release remaining the same.

What exhibit is included in Catalyst Pharmaceuticals’ amended 8-K/A filing?

The amended filing includes Exhibit 99.1, a press release issued on August 26, 2025. This updated release corrects the name of the prior settling party in FIRDAPSE® patent litigation while keeping all other details of the originally disseminated August 25, 2025 press release unchanged.

Why did Catalyst Pharmaceuticals reissue its press release about the FIRDAPSE patent settlement?

Catalyst Pharmaceuticals reissued the press release to fix a misidentified prior settling party. The corrected August 26, 2025 release now names Inventia Healthcare Limited as the entity that previously settled FIRDAPSE® patent litigation, replacing the earlier incorrect reference to Inventia Life Science Pty Ltd.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/28/2025 - 04:30 PM Learn about SEC filing dates

NASDAQtrue0001369568 0001369568 2025-08-25 2025-08-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

(Amendment No. 1)

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): August 25, 2025

CATALYST PHARMACEUTICALS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

Delaware		001-33057		76-0837053
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)
355 Alhambra Circle Suite 801 Coral Gables, Florida (Address of principal executive offices)				33134 (Zip Code)

Registrant’s telephone number, including area code: (305) 420-3200

Not Applicable

Former Name or Former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Name of Exchange on Which Registered		Ticker Symbol
Common Stock, par value $0.001 per share		NASDAQ Capital Market		CPRX

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

EXPLANATORY NOTE

On August 25, 2025, Catalyst Pharmaceuticals, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original 8-K”) with the U.S. Securities and Exchange Commission reporting that the Company had entered into a settlement agreement with Lupin Pharmaceuticals, Inc. and Lupin Ltd. (“Lupin”) resolving certain patent litigation brought by the Company and SERB S.A. against Lupin.

Since the Company disseminated its press release reporting on the settlement with Lupin, the Company has become aware that the Original 8-K and the press release that was an exhibit to the Original 8-K (the “Original Press Release”) inadvertently misidentified one of the parties that had previously settled patent litigation with the Company and SERB S.A. relating to the Company’s FIRDAPSE® patents. The party that previously settled its litigation with the Company and SERB S.A. relating to the Company’s FIRDAPSE® patents is Inventia Healthcare Limited and not Inventia Life Science Pty Ltd.

On August 26, 2025, the Company reissued the Original Press Release to update the identity of the party that previously settled the litigation with the Company and SERB S.A. relating to the Company’s FIRDAPSE® patents. Other than a change to correct the identity of the previous settling party, no other changes were made to the Original Press Release that was disseminated on August 25, 2025.

The updated press release that was disseminated on August 26, 2025 is attached to this Form 8-K/A as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)		Exhibits
99.1		Press release issued by the Company on August 26, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Catalyst Pharmaceuticals, Inc.
By:		/s/ Michael W. Kalb
		Michael W. Kalb
		Executive Vice President and Chief Financial Officer

Dated: August 28, 2025

3